Phaseline

Targets › SLC19A2

SLC19A2 (Thiamine transporter 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Oct 2027.

High-affinity transporter for the intake of thiamine. Mediates H(+)-dependent pyridoxine transport. (UniProt, O60779)

Open in Phaseline: the race on SLC19A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institut National de la Santé Et de la Recherche Médicale, FranceThiamine
Thiamine supplementation to reduce brain injury and cognitive impairment associated with c
SLC19A2, SLC19A3Phase 2Alcohol Use DisorderOct 2027

Conditions

Alcohol Use Disorder (1)

Modalities

small molecule (1)

Companies

Institut National de la Santé Et de la Recherche Médicale, France (1)

Related targets

SLC19A3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.